DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated before the end of 2025Trial builds on positive Phase 1 ...
Ammoxetine, a novel SNRI developed from duloxetine, was effective at treating adults with major depressive disorder (MDD) and ...
Robinhood’s CEO sees tokenization reshaping finance and enabling wider access to assets like stocks and real estate.
The Hearty Soul on MSN
Groundbreaking Progress Made in Huntington's Disease Therapy
The landscape of treating Huntington's disease, a cruel and relentless neurological disorder, may be on the verge of a ...
Background Objective measurements estimated that 1.57 billion people globally had hearing loss in 2019. However, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback